Skip to main content

Analysts’ Top Healthcare Picks: Castle Biosciences (CSTL), Clover Health Investments (CLOV)

Tipranks - Tipranks - Sat Feb 28, 9:56AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Castle Biosciences (CSTL – Research Report) and Clover Health Investments (CLOV – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Castle Biosciences (CSTL)

In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Castle Biosciences, with a price target of $50.00. The company’s shares closed last Friday at $29.71.

According to TipRanks.com, CFA is a 1-star analyst with an average return of -1.4% and a 37.5% success rate. CFA covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Tempus AI, Inc. Class A, and Pacific Biosciences. ;'>

Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $48.83, representing a 63.5% upside. In a report released today, Robert W. Baird also maintained a Buy rating on the stock with a $44.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Clover Health Investments (CLOV)

In a report released yesterday, Richard Close from Canaccord Genuity maintained a Buy rating on Clover Health Investments, with a price target of $3.70. The company’s shares closed last Friday at $2.20.

According to TipRanks.com, Close is a 4-star analyst with an average return of 7.9% and a 47.3% success rate. Close covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Lifestance Health Group, and Privia Health Group. ;'>

Clover Health Investments has an analyst consensus of Moderate Buy, with a price target consensus of $3.23.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).